The United Laboratories (Stock Code: 3933) Announces Approval for UBT251 Injection Clinical Trial

Bulletin Express02-03 18:45

On 2 February 2026, The United Laboratories International Holdings Limited (Stock Code: 3933) reported that its wholly owned subsidiary, The United Bio-Technology (Hengqin) Co., Ltd., gained approval from the China National Medical Products Administration (reference number CXHL2501306) for a clinical trial of UBT251 Injection targeting moderate to severe obstructive sleep apnea (OSA) with obesity.

UBT251 Injection is described as a multi-target peptide receptor agonist acting on the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors, designed to control blood glucose levels and curb weight gain. The company highlights that GLP-1-based weight-loss therapeutics may fill a significant unmet clinical need in addressing OSA.

Phase II clinical trials of UBT251 Injection for overweight or obesity, type 2 diabetes, metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD) have already commenced in China. As the first chemically synthesized GLP-1R/GIPR/GCGR triple agonist new drug in the country, the product represents a key element in The United Laboratories’ research and development efforts.

Looking ahead, The United Laboratories International Holdings Limited intends to continue strengthening its pipeline of innovative biopharmaceuticals with the aim of enhancing its competitiveness and delivering added value to stakeholders. The announcement was dated 3 February 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145231603?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145231603","market":"hk","top_or_hot":-1,"title":"The United Laboratories (Stock Code: 3933) Announces Approval for UBT251 Injection Clinical Trial","media":"Bulletin Express","content":"<p>On 2 February 2026, The United Laboratories International Holdings Limited (Stock Code: 3933) reported that its wholly owned subsidiary, The United Bio-Technology (Hengqin) Co., Ltd., gained approval from the China National Medical Products Administration (reference number CXHL2501306) for a clinical trial of UBT251 Injection targeting moderate to severe obstructive sleep apnea (OSA) with obesity.</p>\n<p>UBT251 Injection is described as a multi-target peptide receptor agonist acting on the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors, designed to control blood glucose levels and curb weight gain. The company highlights that GLP-1-based weight-loss therapeutics may fill a significant unmet clinical need in addressing OSA.</p>\n<p>Phase II clinical trials of UBT251 Injection for overweight or obesity, type 2 diabetes, metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD) have already commenced in China. As the first chemically synthesized GLP-1R/GIPR/GCGR triple agonist new drug in the country, the product represents a key element in The United Laboratories’ research and development efforts.</p>\n<p>Looking ahead, The United Laboratories International Holdings Limited intends to continue strengthening its pipeline of innovative biopharmaceuticals with the aim of enhancing its competitiveness and delivering added value to stakeholders. The announcement was dated 3 February 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The United Laboratories (Stock Code: 3933) Announces Approval for UBT251 Injection Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe United Laboratories (Stock Code: 3933) Announces Approval for UBT251 Injection Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-03 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 2 February 2026, The United Laboratories International Holdings Limited (Stock Code: 3933) reported that its wholly owned subsidiary, The United Bio-Technology (Hengqin) Co., Ltd., gained approval from the China National Medical Products Administration (reference number CXHL2501306) for a clinical trial of UBT251 Injection targeting moderate to severe obstructive sleep apnea (OSA) with obesity.</p>\n<p>UBT251 Injection is described as a multi-target peptide receptor agonist acting on the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors, designed to control blood glucose levels and curb weight gain. The company highlights that GLP-1-based weight-loss therapeutics may fill a significant unmet clinical need in addressing OSA.</p>\n<p>Phase II clinical trials of UBT251 Injection for overweight or obesity, type 2 diabetes, metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD) have already commenced in China. As the first chemically synthesized GLP-1R/GIPR/GCGR triple agonist new drug in the country, the product represents a key element in The United Laboratories’ research and development efforts.</p>\n<p>Looking ahead, The United Laboratories International Holdings Limited intends to continue strengthening its pipeline of innovative biopharmaceuticals with the aim of enhancing its competitiveness and delivering added value to stakeholders. The announcement was dated 3 February 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1145231603","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145231603","pubTimestamp":1770115506,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 2 February 2026, The United Laboratories International Holdings Limited (Stock Code: 3933) reported that its wholly owned subsidiary, The United Bio-Technology (Hengqin) Co., Ltd., gained approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药"},"translate_title":"联邦制药（股票代码：3933）宣布UBT251注射液临床试验获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"On 2 February 2026, The United Laboratories International Holdings Limited (Stock Code: 3933) reported that its wholly owned subsidiary, The United Bio-Technology (Hengqin) Co., Ltd., gained approval from the China National Medical Products Administration (reference number CXHL2501306) for a clinical trial of UBT251 Injection targeting moderate to severe obstructive sleep apnea (OSA) with obesity.\nUBT251 Injection is described as a multi-target peptide receptor agonist acting on the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors, designed to control blood glucose levels and curb weight gain. The company highlights that GLP-1-based weight-loss therapeutics may fill a significant unmet clinical need in addressing OSA.\nPhase II clinical trials of UBT251 Injection for overweight or obesity, type 2 diabetes, metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD) have already commenced in China. As the first chemically synthesized GLP-1R/GIPR/GCGR triple agonist new drug in the country, the product represents a key element in The United Laboratories’ research and development efforts.\nLooking ahead, The United Laboratories International Holdings Limited intends to continue strengthening its pipeline of innovative biopharmaceuticals with the aim of enhancing its competitiveness and delivering added value to stakeholders. The announcement was dated 3 February 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145231603","isCrawlerRequest":true}